Your browser doesn't support javascript.
loading
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas.
Martin, Peter; Furman, Richard R; Rutherford, Sarah; Ruan, Jia; Ely, Scott; Greenberg, June; Coleman, Morton; Goldsmith, Stanley J; Leonard, John P.
Afiliación
  • Martin P; a Department of Medicine , Weill Cornell Medical College , New York , NY , USA.
  • Furman RR; a Department of Medicine , Weill Cornell Medical College , New York , NY , USA.
  • Rutherford S; a Department of Medicine , Weill Cornell Medical College , New York , NY , USA.
  • Ruan J; a Department of Medicine , Weill Cornell Medical College , New York , NY , USA.
  • Ely S; b Pathology and Laboratory Medicine, Weill Cornell Medical College , New York , NY , USA.
  • Greenberg J; a Department of Medicine , Weill Cornell Medical College , New York , NY , USA.
  • Coleman M; a Department of Medicine , Weill Cornell Medical College , New York , NY , USA.
  • Goldsmith SJ; c Department of Radiology , Weill Cornell Medical College , New York , NY , USA.
  • Leonard JP; a Department of Medicine , Weill Cornell Medical College , New York , NY , USA.
Leuk Lymphoma ; 56(11): 3065-70, 2015.
Article en En | MEDLINE | ID: mdl-25754579
Milatuzumab (hLL1), a humanized anti-CD74 monoclonal antibody, has activity in preclinical non-Hodgkin lymphoma (NHL) models. We conducted a phase 1 trial in previously treated B-cell malignancies. Dose escalation included four planned dose levels (1.5, 4, 6 and 8 mg/kg) with milatuzumab given twice weekly for 6 weeks. After dose level 1, the schedule was changed to daily (Monday-Friday) for 10 days. Twenty-two patients were treated. The most common possibly related toxicities were infusion reaction, anemia, lymphopenia, neutropenia and thrombocytopenia. Three patients experienced dose-limiting toxicity (neutropenia, neutropenia, rash) at dose levels 1, 2 and 4, respectively. Eight patients had stable disease, with no objective responses. The serum half-life of milatuzumab was ∼2 h. In seven patients, In-111 imaging showed no clear evidence of tumor targeting. The short half-life may reflect CD74 rapid internalization and presence on extratumoral tissues; this antigen sink must be overcome to capitalize on the promising preclinical activity of the drug.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B / Anticuerpos Monoclonales Humanizados / Antineoplásicos Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B / Anticuerpos Monoclonales Humanizados / Antineoplásicos Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos